筛状结构和导管内癌对接受外照射放疗的Gleason 7前列腺癌的影响
该研究评估了筛状结构和/或导管内癌对接受剂量递增外照射放疗的Gleason 7前列腺癌患者的影响。中位随访117个月,多变量分析显示筛状结构伴导管内癌与更差的无生化复发生存、无远处转移生存和疾病特异性生存相关,而单纯筛状结构无此关联。
要点
- 筛状结构伴导管内癌与更差的无生化复发生存相关(HR 4.22)。
- 筛状结构伴导管内癌与更差的无远处转移生存(HR 4.18)和疾病特异性生存(HR 14.26)相关。
- 单纯筛状结构不伴导管内癌与不良结局无显著关联。
核心结论
- 在接受外照射放疗的Gleason 7前列腺癌男性中,筛状结构伴导管内癌与不良结局相关,而单纯筛状结构不伴导管内癌无此关联。
- 未来研究可能受益于将这两种组织学实体进行二分法分类。
研究设计与样本
- 评估接受剂量递增外照射放疗(联合或不联合雄激素剥夺治疗)的Gleason 7(Grade Groups 2和3)前列腺癌男性。
- 回顾活检标本中筛状结构和/或导管内癌的存在情况。
- 研究终点包括无生化复发生存、无远处转移生存和疾病特异性生存。
- 共237例患者,中位随访117个月(范围3至236个月)。
主要发现
- 根据美国国家综合癌症网络风险分组,24%为有利中危,53%为不利中危,23%为高危。
- 筛状结构不伴导管内癌、筛状结构伴导管内癌、导管内癌不伴筛状结构以及无上述形态的发生率分别为36%、13%、0%和51%。
- 多变量分析显示,筛状结构伴导管内癌(HR 4.22,95%CI 2.08-8.53,p<0.0001)、前列腺特异性抗原10至20 ng/ml(HR 1.97,95%CI 1.03-3.79,p=0.04)和前列腺特异性抗原大于20 ng/ml(HR 2.26,95%CI 1.21-4.23,p=0.01)与更差的无生化复发生存相关。
- 多变量分析显示,仅筛状结构伴导管内癌与更差的无远处转移生存(HR 4.18,95%CI 1.43-12.28,p=0.01)和疾病特异性生存(HR 14.26,95%CI 2.75-74.04,p=0.0016)相关。
- 与筛状结构伴或不伴导管内癌相关的因素包括Grade Group 3、高危组和50%或以上阳性活检针数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the impact of cribriform pattern and/or intraductal carcinoma on Gleason 7 prostate cancer treated with external beam radiotherapy. METHODS: We evaluated men with Gleason 7 (Grade Groups 2 and 3) prostate cancer treated with dose escalated external beam radiotherapy with or without androgen deprivation. We reviewed biopsies for the presence of cribriform pattern and/or intraductal carcinoma. Study end points included biochemical recurrence-free, distant metastasis-free and disease specific survival. RESULTS: In the 237 patients median followup was 117 months (range 3 to 236). According to National Comprehensive Cancer Network® risk groups 24% of patients were at favorable intermediate risk, 53% were at unfavorable intermediate risk and 23% were at high risk. The rate of cribriform pattern without intraductal carcinoma, cribriform pattern with intraductal carcinoma, intraductal carcinoma without cribriform pattern and none of these morphologies was 36%, 13%, 0% and 51%, respectively. On multivariable analysis cribriform pattern with intraductal carcinoma (HR 4.22, 95% CI 2.08-8.53, p <0.0001), prostate specific antigen 10 to 20 ng/ml (HR 1.97, 95% CI 1.03-3.79, p=0.04) and prostate specific antigen greater than 20 ng/ml (HR 2.26, 95% CI 1.21-4.23, p=0.01) were associated with worse biochemical recurrence-free survival. On multivariable analysis only cribriform pattern with intraductal carcinoma was associated with inferior distant metastasis-free survival (HR 4.18, 95% CI 1.43-12.28, p=0.01) and disease specific survival (HR 14.26, 95% CI 2.75-74.04, p=0.0016). Factors associated with cribriform pattern with or without intraductal carcinoma included Grade Group 3, high risk group and 50% or more positive biopsy cores. When stratified by neither morphology present, cribriform pattern without intraductal carcinoma and cribriform pattern with intraductal carcinoma the differences in biochemical recurrence-free, distant metastasis-free and disease specific survival were statistically significant (p=0.00042, p=0.017 and p <0.0001, respectively). CONCLUSIONS: Cribriform pattern with intraductal carcinoma was associated with adverse outcomes in men with Gleason 7 prostate cancer treated with external beam radiotherapy while cribriform pattern without intraductal carcinoma was not so associated. Future studies may benefit from dichotomizing these 2 histological entities.
引用
- Tom MC, Nguyen JK, Lucianò R, et al. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. J Urol. 2019. PMID: 31059665. doi:10.1097/JU.0000000000000316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。